NOVAVAX, INC. (NASDAQ:NVAX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
On April 26 2019, Novavax, Inc. (the Company) executed an Extension of Lease Agreement (Lease Extension) with ARE-Maryland No. 46, LLC (Landlord) extending the term of the existing Lease Agreement between the Company and Landlord dated May 7, 2007 (Lease Agreement) for approximately 51,000 square feet of facility space located at 9920 Belward Drive, Rockville, Maryland. The Lease Extension extends the current Lease Agreement term to January 31, 2024. Under the Lease Extension, the Company will pay approximately $1.7 million per year in base rent.
The foregoing description of the material terms of the Lease Extension is qualified in its entirety by the full terms of the Lease Extension a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
|10.1||Lease Extension for space at 9920 Belward Campus Drive between Novavax, Inc. and ARE-Maryland No. 46, LLC, dated April 26, 2019|
NOVAVAX INC Exhibit
EX-10.1 2 tv520521_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 ACKNOWLEDGMENT OF EXERCISE OF SECOND EXTENSION TERM OPTION AND SECOND EXTENSION TERM COMMENCEMENT DATE This ACKNOWLEDGMENT OF EXERCISE OF SECOND EXTENSION TERM OPTION AND SECOND EXTENSION TERM COMMENCEMENT DATE is made as of this 26th day of April,…
To view the full exhibit click
About NOVAVAX, INC. (NASDAQ:NVAX)
Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).